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Overexpression of chemokine receptor type 4 (CXCR4) has been found to be associated
with increased cell proliferation, metastasis and also act as an indicator of poor
prognosis in patients with breast cancer. Therefore, new agents that can abrogate
CXCR4 expression have potential against breast cancer metastasis. In this study, we
examined the potential effect of thymoquinone (TQ), derived from the seeds of Nigella
sativa, on the expression and regulation of CXCR4 in breast cancer cells. TQ was
found to inhibit the expression of CXCR4 in MDA-MB-231 triple negative breast cancer
(TNBC) cells in a dose- and time-dependent manner. It was noted that suppression
of CXCR4 by TQ was possibly transcriptionally regulated, as treatment with this drug
caused down-regulation of nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-κB) activation and suppression of NF-κB binding to the CXCR4 promoter.
Pretreatment with a proteasome inhibitor and/or lysosomal stabilization did not affect
TQ induced suppression of CXCR4. Down-regulation of CXCR4 was further correlated
with the inhibition of CXCL12-mediated migration and invasion of MDA-MB-231 cells.
Interestingly, it was observed that the deletion of p65 could reverse the observed anti-
invasive/anti-migratory effects of TQ in breast cancer cells. TQ also dose-dependently
inhibited MDA-MB-231 tumor growth and tumor vascularity in a chick chorioallantoic
membrane assay model. We also observed TQ (2 and 4 mg/kg) treatment significantly
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suppressed multiple lung, brain, and bone metastases in a dose-dependent manner in
a metastasis breast cancer mouse model. Interestingly, H&E and immunohistochemical
analysis of bone isolated from TQ treated mice indicated a reduction in number of
osteolytic lesions and the expression of metastatic biomarkers. In conclusion, the results
indicate that TQ primarily exerts its anti-metastatic effects by down-regulation of NF-κB
regulated CXCR4 expression and thus has potential for the treatment of breast cancer.
Keywords: breast cancer, metastasis, thymoquinone, chemokine receptor 4, preclinical “in vivo” study
INTRODUCTION
Breast cancer is the second most common cancer that afflicts
women, with an estimated 1.67 million women diagnosed with
breast cancer in 2012 (Bray et al., 2012; Torre et al., 2015).
Breast cancer ranked fifth in cancer-associated deaths among
all cancers globally in 2012 (Bray et al., 2012; Torre et al.,
2015). While incredible development has been made for the
treatment of breast cancers, the treatment of triple negative breast
cancer (TNBC) is quite a challenge owing to its destructive
features and limited treatment options (Jia et al., 2016; Wang
et al., 2018). Often, chemotherapy for breast cancer is ridden
with side effects and drug resistance, leading to failure in
therapy. Compelling evidence suggests that if breast cancer
metastasis to distant site organs can be prevented, then it is an
indicator for good prognostic outcome (Alvarez et al., 2010; Perez
and Spano, 2012). Interactions between chemokines and their
cognate receptors play important roles in tumor metastasis. The
interaction between chemokine receptor type 4 (CXCR4) and
its cognate ligand stromal-derived factor-1 (SDF1 or CXCL12)
plays a crucial role in the regulation of migration and metastasis
in a variety of solid tumors including breast cancer (Balkwill,
2004a,b). Moreover, SDF1 has been found to be frequently over-
expressed in lymph nodes, lung, liver, and bone marrow (Muller
et al., 2001; Keeley et al., 2010). Hence, in the present study,
we investigated the effect of thymoquinone on the SDF1/CXCR4
signaling axis.
Numerous novel bioactive compounds have been reported in
several parts of medicinal plants that play an essential role in
the prevention and treatment of chronic inflammation driven
cancers (Shanmugam et al., 2011a, 2012, 2015, 2016; Sethi et al.,
2012; Yang et al., 2013; Tang et al., 2014; Bishayee and Sethi,
2016; Hasanpourghadi et al., 2017). Thymoquinone (TQ) is
one of the volatile bioactive constituents of Nigella sativa seed
oil. Various studies have reported the anti-inflammatory, anti-
oxidant, and anti-cancer properties of TQ both in vitro and
in vivo (Shanmugam et al., 2018). TQ has been found to inhibit
breast, ovarian, pancreatic, colon adenocarcinoma (Worthen
et al., 1998; Shoieb et al., 2003; Gali-Muhtasib et al., 2004; Woo
et al., 2012, 2013), human osteosarcoma (Roepke et al., 2007),
lung carcinoma (Kaseb et al., 2007), myeloblastic leukemia (El-
Mahdy et al., 2005), and multiple myeloma (Li et al., 2010; Siveen
et al., 2014b) by modulation of diverse molecular targets that
are involved in cell proliferation, survival, invasion, metastasis,
and angiogenesis. In vivo TQ has been reported to inhibit the
growth of tumors (Salem, 2005; Gali-Muhtasib et al., 2006; Woo
et al., 2013). Moreover, TQ has been found to down-regulate
inducible nitric oxide synthase and cyclooxygenase-2 (COX-2)
(El-Mahmoudy et al., 2002; El Mezayen et al., 2006).
The master transcription factor nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) plays a pivotal role
in the development and progression of inflammation-driven
diseases including cancer (Dey et al., 2008; Sethi et al., 2008b,
2012; Sethi and Tergaonkar, 2009; Shanmugam et al., 2013;
Li et al., 2015; Liu et al., 2018; Puar et al., 2018). In human
chronic myeloid leukemia cells (KBM-5), TQ was reported to
abrogate NF-κB activation and augment cellular apoptosis (Sethi
et al., 2008a). Several other studies have shown that TQ can also
down-regulate protein kinase B and extracellular receptor kinase
signaling pathways (Yi et al., 2008). Woo et al., 2011 reported
that TQ can exert a strong anti-proliferative effects in TNBC cells
by activating peroxisome proliferator-activated receptor gamma
(PPARγ) (Woo et al., 2011). TQ administered intraperitoneally,
has been found to be well tolerated up to 22.5 mg/kg in male rats
and 15 mg/kg in female rats; whereas for TQ administered orally,
the dose was as high as 250 mg/kg in both male and female rats
(Abukhader, 2012).
Our prior published data has already indicated that TQ
can exert anti-cancer effects on MCF7 breast cancer cells
through activation of the PPARγ signaling cascade (Woo et al.,
2011). In a recent study TQ was shown to suppresses the
proliferation, migration, and invasion of metastatic MDA-MB-
321 breast cancer cells by inhibiting the p38 mitogen-activated
protein kinase pathway in vitro and in vivo (Woo et al., 2013).
Therefore, we postulated that TQ may modulate the expression
of CXCR4 and inhibit tumor metastasis in vivo. Our results
indicate that TQ can down-regulate CXCR4 expression and
CXCL12-induced migration and invasion in breast cancer cell
lines through inhibition of NF-κB activation. Furthermore, we
tried to investigate the effect of TQ on experimental metastasis
that involved the injection of breast cancer cells directly into the
systemic circulation (Hwang et al., 2015).
Breast cancer has a greater tendency to spread to the bone
marrow of the femora, tibiae, and the mandibular bones.
Therefore, intracardiac injection method has been employed to
develop osteolytic bone metastasis model (van der Horst and van
der Pluijm, 2012; Kumar and Manjunatha, 2013; Lee et al., 2014).
On the basis of the crucial role of SDF1/CXCR4 in breast cancer
metastasis to femora, tibiae, and mandibles, we systemically
injected via an intracardiac route MDA-MB-231-luc+ cells to test
the ability of TQ to modulate CXCR4 expression and thereby
inhibit metastasis to the bones and other organs.
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MATERIALS AND METHODS
Cell Lines
Human breast cancer MCF7, MDA-MB-231, and BT-549 were
purchased from ATCC (Manassas, VA, United States). The
MDA-MB-231-luciferase expressing cell line was purchased from
Cell Biolabs, United States. The cells were cultured in DMEM
supplemented with 10% fetal bovine serum (FBS) and antibiotics
penicillin/streptomycin.
Materials
Thymoquinone (TQ), N-Acetyl-L-leucyl-L-leucyl-L-norleucinal
(ALLN), chloroquine, formic acid, Tris, glycine, NaCl, sodium
dodecyl sulfate (SDS), crystal violet, and bovine serum
albumin were purchased from Sigma-Aldrich (St. Louis,
MO, United States). A 50 mM solution of TQ was prepared
with dimethyl sulfoxide (DMSO) and stored as small aliquots
at −20◦C. RPMI 1640, FBS, antibiotic-antimycotic mixture,
and lipofectamine were obtained from Invitrogen (Carlsbad,
CA, United States). Antibody against CXCR4 (polyclonal) was
obtained both from Abcam (Cambridge, MA, United States)
and Santa Cruz Biotechnology (Santa Cruz, CA, United States).
CXCL12 was purchased from ProSpec-Tany TechnoGene,
Ltd. (Rehovot, Israel). Antibody against β-actin (monoclonal),
control siRNA and p65 siRNA was obtained from Santa
Cruz Biotechnology (Santa Cruz, CA, United States). Ki-67
polyclonal antibody, Lamin B1, phospho-p65 (Ser 536), and
p65 monoclonal antibodies were obtained from Cell Signaling
Technology (Beverly, MA, United States). Goat anti-rabbit-
horseradish peroxidase (HRP) conjugate and goat anti-mouse
HRP were purchased from Sigma-Aldrich (St. Louis, MO,
United States). D-Luciferin Firefly potassium salt was purchased
from Gold Biotechnology, United States. Formic acid was
purchased from Sigma-Aldrich (St. Louis, MO, United States).
The NF-κB luciferase plasmid was obtained from Stratagene (La
Jolla, CA, United States). The Bradford protein assay reagent
was purchased from Bio-Rad Laboratories (Hercules, CA,
United States). Isoflurane for anesthesia was purchased from
National University of Singapore, Animal holding unit pharmacy
(Singapore).
Western Blotting
Vehicle or TQ-treated breast cancer cell lines and tumor tissues
obtained from the mouse study were lysed in RIPA lysis buffer
(Li et al., 2010). Nuclear extracts of TQ treated or control cells
were prepared using TransAM nuclear extract kit according to
the manufacturer’s instructions. Whole cell lysates was resolved
on a 10% SDS polyacrylamide gel electrophoresis (SDS–PAGE)
gel. The proteins were electro-transferred to a nitrocellulose
membrane (Bio-Rad), blocked with Blocking One (Nacalai
Tesque, Inc.), and probed with antibodies of interest overnight
at 4◦C. The blot was washed with tris-buffered saline with 0.1%
Tween-20, exposed to HRP-conjugated secondary antibodies for
1 h, and finally examined by chemiluminescence using Western
Bright Sirius HRP substrate (Advansta). Images were captured
using a ChemiDoc XRS+ imaging system and analyzed using
Image LabTM software (Bio-Rad, Hercules, CA, United States) as
described previously (Chua et al., 2010). Densitometric analysis
was done using ImageJ software.
NF-κB Reporter Assay
MDA-MB-231 and BT-549 cells were plated in 6-well plates
with 1 × 104 cells per well in complete medium. The following
morning, cells were transfected with an NF-κB reporter plasmid
linked to a luciferase gene or with the dominant-negative
IκBα (IκBα-DN) plasmid, co-transfected with a β-galactosidase
plasmid (Promega, Madison, WI, United States). Transfections
were done according to the manufacturer’s protocols using
Lipofectamine (Invitrogen, United States). At 24 h post-
transfection, cells were treated with TQ (50 µM) for indicated
time points and then washed and lysed in luciferase lysis
buffer (Promega). Luciferase activity was measured using a
Tecan plate reader (Durham, NC, United States) by using
a luciferase assay kit (Promega) and was normalized to
β-galactosidase activity. All luciferase experiments were done
in triplicate as previously described (Shanmugam et al.,
2011b).
NF-κB DNA-Binding Activity Assay
To determine NF-κB activation, nuclear extracts were prepared
using a nuclear extraction kit (Active Motif, Carlsbad, CA,
United States) according to the manufacturer’s instructions.
NF-κB DNA-binding activity was analyzed using the TransAM
NF-κB p65 transcription factor assay kit (Active Motif,
Carlsbad, CA, United States), following the manufacturer’s
instructions. The enzymatic product was measured at 450 nm
with a microplate reader (Tecan Systems, San Jose, CA,
United States) as previously described (Shanmugam et al.,
2011b).
Chromatin Immunoprecipitation and
Quantitative RT-PCR
Human MDA-MB 231 and BT-549 TNBC cells were seeded in
15-cm culture dishes and treated with TQ (50 µM) for 0, 2, 4,
6, and 8 h. At the end of the treatment period the cells were
fixed with 1% formaldehyde at room temperature for 10 min and
neutralized with glycine. The cells were collected, resuspended
in CHIP lysis buffer, and sonicated (Vibra-Cell,TM Newtown,
CT, United States). Samples were incubated with protein-G
beads that had been pre-incubated with 4–10 µg of anti-NF-
κB antibody (Cell Signaling Technology, MA, United States)
or negative control IgG (Sigma-Aldrich Co., St. Louis, MO,
United States). The next day, immunoprecipitants were washed
by using washing buffer and reverse cross-linked at 65◦C.
The DNA was then purified by using a PCR purification
kit purchased from MACHEREY-NAGEL (Duren, Germany).
Finally, the purified DNA was subjected to quantitative RT-PCR
and data analyzed.
Scratch Wound Healing Assay
MDA-MB-231 and BT-549 cells were seeded in culture plate
containing a culture-insert (Ibidi, Martinsried, Germany) until
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fully confluent. A cell-free gap of 500 µm was created after
removing the culture-insert. After incubation with 50 µM
TQ for 12 h, the medium was changed to medium with
or without CXCL12. After migration for 8 or 24 h, the
wound distance was observed and captured using bright field
microscopy and the gap distance was measured using Photoshop
software (Manu et al., 2011; Shanmugam et al., 2011b,c). MDA-
MB-231 cells were transfected with 50 nmol/L of p65 or
control siRNA. The cells were then subjected to wound healing
assay either in the presence or absence of TQ (50 uM) for
8 h.
Invasion Assay
An in vitro cell invasion assay was performed using a BioCoat
Matrigel invasion assay system (BD Biosciences, San Jose, CA,
United States), as described previously (Manu et al., 2013;
Shanmugam et al., 2011b,c). MDA-MB-231 cells were transfected
with 50 nmol/L of p65 or control siRNA. The cells were then
subjected to invasion assay either in the presence or absence of
TQ (50 uM) for 8 h.
Determination of Tumor Growth Using a
Chick Choriallantoic Membrane Assay
The chick chorioallantoic membrane (CAM) assay was modified
from Sys et al. (2013). Briefly, fertilized chicken eggs (Bovans
Goldline Brown) were purchased from Chew’s Agriculture Pte
Ltd., Singapore and placed horizontally in a 37.5◦C incubator
with 70% humidity on embryonic day (ED)-0. On ED-3, a sharp
weighted tool was used to poke a hole at the apex of the eggshell,
and 3 mL of albumin was removed using a 5 mL syringe and
18G needle in order to drop the CAM. The sharp weighted tool
was then used to poke a hole in the middle of the egg before
using curved surgical scissors to cut a 1 cm2 hole. The eggs were
screened and dead embryos were removed. The hole was then
sealed with a 1624W Tegaderm semi-permeable membrane and
the egg placed back into the incubator. On ED-7, MDA-MB-
231 (0.65 × 106) cells were mixed with matrigel. Fifty micro
liter of the matrigel-cell mixture was placed on the CAM/egg.
The hole was then re-sealed with the Tegaderm semi-permeable
membrane. Twenty micro liter of DMSO or 25, 50, or 100 µM of
TQ was added by pipetting onto autoclaved filter paper disks on
ED-10 after the initial ultrasound scan. The tumor volume and
tumor vascularity was determined at the 72 h time point in the
control and TQ treated groups.
Ultrasound Imaging
On embryonic day 10, and after 72 h incubation with or without
TQ, the Tegaderm membrane was removed and Aquasonic gel
was added onto cling wrap that had been carefully placed over the
CAM tumors. Using a VisualSonics Vevo 2100 Imaging system,
a 550D transducer connected to a 3D acquisition monitor was
used to obtain ultrasound images of the tumors formed on the
CAM. Parallel 2D sections obtained were further reconstructed
to form 3D images of the tumors. Tumor volumes and percentage
of vasculature were calculated using the Vevo Lab 1.7.0 program.
On ED-13, after ultrasound imaging, the CAM tumors, along
with chick liver (to check for metastasis) were carefully excised
and washed in PBS, part of it was snap frozen in liquid nitrogen
for molecular analysis while the other part was fixed in 10%
formalin overnight at 4◦C, before being embedded in paraffin.
The paraffin blocks were then taken for future histopathological
analysis.
Intracardiac Experimental Metastasis
Murine Model
All procedures involving animals were reviewed and approved
by the NUS Institutional Animal Care and Use Committee.
Seven week old NCr-Foxn1nu, female mice were purchased
from InVivos Pte Ltd., Singapore. NCr-Foxn1nu female mice
were intracardially implanted with 1 × 106 MDA-MB-231-luc+
cell line. Female nude mice (age 7 weeks) were anesthetized
with 3–5% isoflurane. On day 0, anesthetized animals were
injected with 1 × 106 MDA-MB-231-luc+ cells suspended in
100 µl sterile Dulbecco phosphate buffered saline (DPBS) into
the left ventricle of the heart by non-surgical means (Contag
et al., 2000). D-Luciferin potassium salt (Gold Biotechnology, St.
Louis, MO, United States) at room temperature was dissolved in
DPBS without calcium or magnesium to a final concentration
of 15 mg/ml. The luciferin solution was sterilized using a
0.22 micron filter and then injected intraperitoneally at a
concentration of 150 mg/kg body weight (b.w). The mice
were placed in an imaging chamber and imaged both on the
dorsal and ventral sides whilst under isoflurane anesthesia (3–
5%) using an IVISTM Imaging System (Xenogen Corporation,
United States), for 20 s–3 min as described previously
(Rehemtulla et al., 2000; Jenkins et al., 2003a,b; Scatena et al.,
2004).
A successful intracardiac injection was indicated on
day 0 by images showing systemic bioluminescence
distributed throughout the animal. Only mice indicating
a satisfactory injection were included in the experimental
groups. The mice were imaged once every week for
tumor cell metastasis for a total of 4 weeks. Generally,
two to three mice were imaged at a time. Imaging
and quantification of signals were controlled by the
acquisition and analysis software Living Image R© (Xenogen R©
Corporation, United States). Tissues of interest were excised,
placed into 24-well tissue culture plates with 300 µg/ml
D-luciferin in DPBS and imaged for 1–2 min. Tissues were
subsequently fixed in 10% formalin (Sigma, St. Louis, MO,
United States) and prepared for standard histopathology
evaluation.
Hematoxylin and Eosin Staining
At the end of treatment, mice hind limbs and fore limbs
were collected and fixed in 10% neutral buffered formalin
solution (Sigma-Aldrich, St. Louis, MO, United States).
The limbs’ muscle tissue was then removed to expose the
bone. The bones were then decalcified by soaking in citric
acid buffered formic acid (Sigma-Aldrich, St. Louis, MO,
United States) for 96 h. The softened and decalcified bone
was then processed and embedded into paraffin wax blocks.
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FIGURE 1 | (A) The chemical structure of thymoquinone (TQ). (B) Western blot analysis of CXCR4 expression in breast cancer cells. TQ down-regulated the
expression of CXCR4 in a dose-dependent manner. MCF7 (left panel) and MDA-MB-231 cells (right panel) were incubated with the indicated concentration of TQ for
12 h. Fifty micro gram of whole cell extracts of MCF7 and MDA-MB-231 cells were resolved on SDS–PAGE gel and probed with anti-CXCR4 antibody. The
membrane were stripped and re-probed with anti-actin antibody to determine equal protein loading. (C) TQ suppressed CXCR4 expression in a time-dependent
manner. MCF7 (left panel) and MDA-MB-231 (right panel) breast cancer cells were treated with 40 µM of TQ for the indicated time and Western blot analysis was
performed as describe above. The blots were stripped and probed for actin as loading control. (D) TQ mediated suppression of CXCR4 was not through the
proteasomal pathway. MDA-MB-231 cells (left panel) and BT-549 cells (right panel) were treated with the indicated concentration of ALLN for 1 h at 37◦C followed by
TQ (50 µM) for 12 h. Whole cell extracts were then subjected to Western blot analysis and probed for CXCR4. The same blots were then re-probed for actin to show
equal protein loading. (E) TQ mediated suppression of CXCR4 was not through the lysosomal pathway. BT-549 cells were treated with the indicated concentration of
chloroquine for 1 h at 37◦C followed by TQ (50 µM) for 12 h. Whole cell extracts were then subjected to Western blot analysis and probed for CXCR4. The same
blots were then reprobed for actin to show equal protein loading.
The bone samples were then sectioned and stained with
hematoxylin and eosin solution (Merck, Germany). Images
were taken using an Olympus BX51 microscope (magnification,
40×).
Immunohistochemical (IHC) Analysis of
Tumor Samples
Breast cancer tumor cells that had metastasized to the bone,
lung, and brain from control and drug-treated groups were fixed
with 10% phosphate buffered formalin, processed, and embedded
in paraffin. The bone and tumor sections, 5 µM in thickness,
were cut and deparaffinized in xylene, dehydrated in graded
ethanols, and finally hydrated in water. Antigen retrieval was
conducted by boiling the slide in 10 mM sodium citrate (pH
6.0) for 30 min. Sections were incubated overnight with anti-
CXCR4 primary antibody (1:100 dilutions). IHC was conducted
following the manufacturer’s instructions (Dako LSAB Kit) as
described previously (Dai et al., 2015; Zhang et al., 2016). Images
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FIGURE 2 | TQ modulates constitutive NF-κB activation in MDA-MB-231 and BT-549 cells. (A) Both breast cancer cell lines were incubated with 50 µM TQ for the
indicated time points. The cells were then lysed in a hypotonic buffer and the nuclear extracts were prepared and assayed for NF-κB activation using TransAM p65
transcription factor assay kit. (B) Both MDA-MB-231 and BT-549 cells were transiently transfected with NF-κB luciferase plasmid and co-transfected with
β-galactosidase plasmid for 6 h. The medium was changed and then treated with 50 µM TQ or inhibitory kappaB (IκB) plasmid for the indicated time points. The
cells were then lysed in reporter lysis buffer (Promega Inc.) and assayed for luciferase activity as described in the Materials and Methods. Results are plotted as fold
activity compared to vector only control. Bars indicate standard error. ∗ Indicates p-value < 0.05. (C,D) TQ inhibits binding of NF-κB to the CXCR4 promoter.
MDA-MB-231 cells (C) and BT-549 cells (D) were treated with 50 µM TQ for the indicated time points and the proteins were then cross-linked with DNA using
formaldehyde and then processed for chromatin immunoprecipitation assay using anti-p65 antibody with CXCR4 primers as described in materials and methods.
(E) Effect of TQ on p65 expression and phosphorylation in MDA-MB-231 cells. Nuclear extracts were prepared as described in Materials and Methods.
MDA-MB-231 cells were treated with TQ at doses of 25 and 50 µM for 8 h and expression of various proteins was analyzed by western blot analysis. (F) TQ
suppressed CXCL12 induced CXCR4 expression. MDA-MB-231 breast cancer cells were treated with 50 µM of TQ for 8 h, whole cell extracts was prepared and
Western blot analysis was performed as describe in Materials and Methods. The blots were stripped and probed for actin as loading control.
were taken using an Olympus BX51 microscope (magnification,
40×). Quantitative analysis of IHC images was performed by
visual scores between the control and treated images. In this
expression quantitation technique, each image was divided into
four parts and each part was individually quantitated for the
biomarker expression. A cell scored as positive refers simply to
the presence of brown staining (peroxidase) in any part of the
studied tissue. A negative cell scored refers to no staining or weak
staining.
Statistical Analysis
Student t-test was used to analyze the data. For in vivo
studies, unpaired t-test was used for statistical comparisons
between groups. p < 0.05 was considered statistically
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FIGURE 3 | TQ abrogates invasion and migration of breast cancer cells. (A,B) Effect of TQ on invasion of MDA-MB-231 cells (A) and BT-549 cells (B). The cells
were seeded in the top side of the chamber and matrigel was coated as a layer on the bottom side of the chamber. The cells were pretreated with or without TQ
(50 µM) for 12 h and the cells were then seeded in the top chamber and placed in a 24 well plate containing either the basal medium only or basal medium
containing 100 ng/ml CXCL12 for 24 h. The invaded cells were then fixed and stained with 1% crystal violet solution. Columns represent the number of cells
invaded. Bars indicate standard error. ∗ Indicates p-value < 0.05. (C,D) Effect of TQ on migration of MDA-MB-231 and BT-549 cells. A scratch wound healing assay
was performed to evaluate the inhibitory effect of TQ on breast cancer cell migration. A chamber containing 500 micron size cell free width was measured on day 0
and after incubation with 50 µM TQ for 12 h, the medium was changed to medium with or without CXCL12 (100 ng/ml). After migration for 24 h, the gap distance of
the wound was measured at three different sites. Bars indicate standard error. ∗ Indicates p-value < 0.05. (E) MDA-MB-231 cells were transfected with 50 nmol/L of
p65 or control siRNA. The cells were then subjected to invasion assay either in the presence or absence of TQ (50 µM) for 8 h. (F) MDA-MB-231 cells were
transfected with 50 nmol/L of p65 or control siRNA. The cells were then subjected to migration assay either in the presence or absence of TQ (50 µM) for 8 h.
∗ Indicates p-value < 0.05; ∗∗ Indicates p-value < 0.005.
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significant (GraphPad Prism 5.0; GraphPad Software, CA,
United States).
RESULTS
The present study was designed to investigate the effect of TQ
(with structure shown in Figure 1A) on both CXCR4 expression
and function in BT-549 and MDA-MB-231 TNBC cells and in a
metastatic murine model.
TQ Suppresses CXCR4 Protein
Expression in Breast Cancer Cells
We first studied the effect of TQ on the expression of CXCR4 in
MCF7 and MDA-MB-231 breast cancer cell lines. We observed
that TQ could suppress the expression of CXCR4 in a dose- and
time-dependent manner in MCF7 (Figures 1B,C, left panel) and
MDA-MB-231 (Figures 1B,C, right panel), respectively.
Down-Regulation of CXCR4 Expression
by TQ Is Not Mediated Through Its
Degradation
Previous studies have shown that CXCR4 undergoes
ubiquitination at its lysine residue, followed by degradation
(Kukreja et al., 2005; Shanmugam et al., 2011b); hence, we
next examined the likelihood that TQ may augment the rate of
CXCR4 degradation through the stimulation of proteasomes.
MDA-MB-231 and BT-549 cells were pretreated with ALLN, a
proteasome inhibitor, for 1 h before treating with TQ. As shown
in Figure 1D, ALLN did not protect TQ-induced degradation of
CXCR4, thereby indication that this is an improbable basis for
the downregulation of CXCR4 expression by TQ. In addition we
also studied the capability of chloroquine, a lysosomal inhibitor,
to abrogate TQ-induced degradation of CXCR4, as CXCR4 has
been shown to undergo ligand-dependent lysosomal degradation
(Shanmugam et al., 2011b). Both the cell lines were pretreated
with chloroquine for 1 h before being treated with TQ. Our
results indicated that chloroquine at 200 µM only marginally
prevented the degradation of CXCR4 (Figure 1E), thereby
suggesting that this was possibly not the main pathway for
suppression of expression of CXCR4.
TQ Modulates Constitutive Activation of
NF-κB in TNBC Cells
The NF-κB pro-survival signaling pathway plays a critical role in
breast cancer cell progression and metastasis (Helbig et al., 2003).
The promoter region of the CXCR4 gene also has several NF-κB
binding sites (Shanmugam et al., 2011b). Therefore it is possible
that TQ suppresses NF-κB activation and downregulate CXCR4
expression. We found that treatment with TQ suppressed NF-κB
activation in a time-dependent manner (Figure 2A). This result
suggests that TQ may down-regulate CXCR4 expression through
inhibition of NF-κB activation. However, DNA binding alone is
not always associated with NF-κB -dependent gene transcription,
suggesting that added controlling steps are involved. Subsequent
results also indicated that TQ inhibited NF-κB reporter activity
FIGURE 4 | TQ abolishes the growth of MDA-MB-231 breast tumor cells
inoculated onto chick chorioallantoic membrane and suppresses tumor
vascular volume. (A) Representative images of MDA-MB-231 chorioallantoic
membrane (CAM) tumors excised from the CAM. 0.65 × 106 MDA-MB-231
cells were inoculated onto the CAM on embryonic day 7. The tumors were
imaged by ultrasound on embryonic day 10. After the initial ultrasound, 20 µl
of DMSO or 25, 50, or 100 µM TQ was added to the autoclaved filter paper
disks kept on the CAM. A final ultrasound was taken on embryonic day 13
after 72 h treatment. (B,C) Effects of TQ on the growth of CAM tumor and
tumor vascular volume. Tumor volumes were calculated using the Vevo Lab
1.7.0 program by tracing out the boundaries of the tumor and reconstruction
of the 2D images. For each condition (n = 4) tumors were obtained and the
average percentage change in tumor volumes (B) and percentage change in
tumor vascular volumes were calculated (C). DMSO-treated CAM tumors
were significantly bigger and more vascularized than the TQ-treated tumors.
Bars indicate standard error. ∗ Indicates p-value < 0.05.
in a time-dependent manner in TNBC cells (Figure 2B). As
both phosphorylation and nuclear translocation are critical for
the function of transcription factors, we next evaluated the
effect of TQ on nuclear translocation of p65 and phospho-
p65 expression by Western blot analysis. We found that TQ
dose-dependently suppressed nuclear accumulation of p65 and
phospho-p65 expression in the nucleus of MDA-MB-231 cells
(Figure 2E).
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TQ Abrogates CXCL12-Induced
Over-Expression of CXCR4
Chemokine receptor type 4 is one of the most important
chemokine receptors in TNBC. High CXCR4 expressing tumor
cells have a greater invasive and metastatic potential, and
CXCR4+ cells migrate following a concentration gradient of
CXCL12. Overexpression of this receptor has been observed in
patients who exhibit advanced stages of cancer and metastasis
and correlates with worse prognosis and decreased patient
survival (Kato et al., 2003). We next investigated if indeed TQ
can suppress CXCL12 induced overexpression of CXCR4 in
MDA-MB-231 cells. Interestingly, we found that TQ suppressed
CXCL12 induced over-expression of CXCR4 in MDA-MB-231
cells thereby indicating that positive feedback loop between
CXCR4 and downstream signaling components may be mediated
in an autocrine manner (Figure 2F).
TQ Attenuates NF-κB Transcriptional
Activity by Decreasing Its Binding to the
CXCR4 Promoter
Whether the down-regulation of CXCR4 by TQ in TNBC cells
was due to suppression of NF-κB activation in vivo was examined
by a ChIP assay targeting NF-κB binding in the CXCR4 promoter.
We found that TQ suppressed NF-κB binding to the CXCR4
promoter (Figures 2C,D) in both the TNBC cell lines, thereby
indicating that TQ inhibits CXCR4 expression by suppressing
NF-κB binding to the CXCR4 promoter. According to the
quantitative RT-PCR result, compared to the untreated samples,
TQ significantly decreased the binding of NF-κB to the CXCR4
promoter and this reduction was noted to occur in a time-
dependent fashion (Figures 2C,D).
TQ Inhibits CXCL12-Induced Cellular
Invasion and Migration
We further elucidated the effect on TQ on CXCL12-induced
cell invasion. Using an in vitro invasion assay, TQ treatment
suppressed CXCL12-induced invasion in both the cell lines
(Figures 3A,B). Furthermore, we performed addition experiment
by using p65 siRNA to inhibit the NF-κB signaling pathway
and to determine the anti-invasive potential of TQ on MDA-
MB-231 cells. Interestingly, we found that upon inhibition of
NF-κB, TQ was not able to significantly mitigate cellular invasion
(Figure 3E). Whether the down-regulation of CXCR4 by TQ
correlates with cell migration was also examined using an in vitro
scratch wound healing assay. We found that both MDA-MB-
231 and BT-549 cells migrated faster under the influence of
CXCL12 and this effect was abolished on treatment with TQ
(Figures 3C,D). Interestingly, we found that upon inhibition
of NF-κB using p65 siRNA, TQ was not able to significantly
attenuate cellular migration (Figure 3F).
TQ Abolishes Tumor Growth and
Vascular Volume in a CAM Assay Model
We evaluated the effect of TQ on the growth of tumors in a CAM
assay model. We found that 3D ultrasound scanning of tumors
indicated that TQ could inhibit the growth of tumors in a dose-
dependent manner. TQ at doses of 50 and 100 µM significantly
inhibited the growth of tumors compared to the vehicle control
group (Figure 4B), and potently reduced the tumor vascular
volume at doses of 50 and 100 µM, thereby indicating complete
abrogation of tumor vasculature by TQ (Figure 4C). However,
TQ at the lower dose of 25 µM had no effect on tumor growth
and vascularity. Photographic images of CAM vehicle treated and
TQ treated CAM tumors are shown in Figure 4A.
TQ Inhibits Breast Cancer Bone
Metastasis and Thinning of Bones
To investigate whether TQ can suppress bone metastasis, 8 weeks
old nude mice were injected intracardiac with MDA-MB-231-
luc+ expressing cells and then treated with TQ 2 mg or 4 mg/kg
b.w. intraperitoneally for 4 weeks. The mice were divided into
three groups and the schematic of the TQ dosing regimen
is shown in Figure 5B. Bioluminescence images showed a
decrease in number of colonies metastasized to distant site organs
compared to vehicle control animals (Figure 5A). A significant
dose-dependent, anti-metastatic effect was observed in the lung
tissue (Figure 5C) and in the brain tissue (Figure 5D). High
CXCR4 expressing MDA-MB-231 cells always tend to move to
a region rich in CXCL12 such as bone marrow (Fernandis et al.,
2004; Hung et al., 2014). By the third and fourth week we detected
bone metastasis. At 4 weeks, metastatic activity was greater in
control mice compared to TQ treated mice (Figure 5E).
Remarkably, it was found that TQ significantly suppressed
the metastasis of breast cancer cells to the bone (Figure 5E),
and also there was a decrease in the metastatic sites such as
bone marrow of the femora, tibiae, and mandibles. We observed
a decrease in metastatic osteolytic lesions using H&E staining,
and a significant decrease in the bone colonization of breast
cancer cells (Figure 6B). A similar anti-metastatic effect was also
observed in the lung (Figure 5C) and brain tissues (Figure 5D).
In addition, no significant decrease in the body weight was
observed both in the vehicle treated control and TQ treatment
group (data not shown). H&E examination of the bone sections
revealed prevention of thinning of bones in the TQ treated group
as compared to control mice (Figure 6B).
TQ Reduces the Expression of NF-κB
Regulated Gene Products in the Tumor
Tissues
NF-κB regulates the expression of several genes that are involved
in tumor growth, metastasis, and angiogenesis (Li et al., 2015).
A dose-dependent decrease in the expression of NF-κB-regulated
proteins (CXCR4 and Ki-67) in the lung and brain tissues was
observed by immunoblot analysis (Figure 6A). As shown in
Figure 6C, TQ treatment inhibited CXCR4 expression in bone
(top panel), lung (middle panel), and brain tissues (bottom
panel), that was assessed by IHC analysis. A marked decrease in
the expression of CXCR4 was observed in the femur of mice, and
a similar effect was observed in the lung and brain tissues treated
with TQ (4 mg/kg b.w.).
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FIGURE 5 | Anti-metastatic activity of TQ in a breast cancer metastatic model. (A) Representative images of bioluminescence imaging of mouse. (B) Schematic of
dosing regimen. TQ at either 2 mg/kg or 4 mg/kg body weight was administered for 4 weeks. (C) Relative lung tumor metastasis in athymic nude mice bearing
intracardially injected MDA-MB-231-Luc+ cells treated with either corn oil or with TQ (2 or 4 mg/kg b.w) for 4 weeks. (D) Relative brain tumor metastasis as
determined by bioluminescence imaging. (E) Relative bone tumor metastasis as determined by bioluminescence imaging. Bars indicate standard error. ∗ Indicates
p-value < 0.05.
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FIGURE 6 | TQ abrogates the expression of metastatic genes in tumor tissue. (A) Metastatic lung (left panel) and brain (right panel) tumor tissue obtained from either
vehicle control or TQ treated mice was lysed and subjected to Western blot analysis. Fifty micro gram of whole cell extracts were resolved in SDS–PAGE gel and
probed for anti-CXCR4, anti-Ki67, and anti-β-actin. The membrane were stripped and re-probed with anti-actin antibody to determine equal protein loading.
(B) Hematoxylin and eosin staining of metastatic femur bone obtained from normal mice, vehicle control mice, and TQ treated mice. B, trabecular bone; BM, bone
marrow, black arrows indicate osteolytic lesion (OL) of trabecular bone. Images were taken using an Olympus BX51 microscope (magnification, 40×).
(C) Immunohistochemical analysis of metastatic bone, lung, and brain tumor tissue. (C) Top panel, metastatic tissue obtained bone was stained for CXCR4
expression. A marked decrease in the expression of CXCR4 was observed in the femur of mice treated with TQ (4 mg/kg b.w.). A similar decrease in the expression
of CXCR4 was observed in both lung [(C) middle panel] and brain tissue [(C) lower panel]. Images were taken using Olympus BX51 microscope (magnification, 40×).
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DISCUSSION
The current study was designed to investigate the anti-metastatic
effect of TQ, and its underlying molecular mechanisms of action
in TNBC cell lines in vitro and in an intracardiac metastatic
murine model. CXCR4 over-expression has been associated
with tumor cell proliferation, invasion, and metastasis. TQ
was found to inhibit the expression of CXCR4 in MDA-MB-
231 and MCF7 breast cancer cell lines, irrespective of the cell
type and HER2 status. We further observed that TQ inhibited
constitutive NF-κB DNA binding and activation in both the
TNBC cell lines and significantly suppressed NF-κB dependent
luciferase expression. These results are in line with previous work
showing that TQ can abrogate NF-κB activation pathway (Sethi
et al., 2008a; Siveen et al., 2014b) in diverse cells. Interestingly,
TQ mediated down-regulation of CXCR4 did not occur by
proteolytic degradation of the receptor but rather by a decrease in
the number of transcripts. In addition, inhibition of the CXCR4
receptor was associated with down-regulation of migration and
invasion of TNBC cells upon stimulation with its ligand CXCL12.
Numerous reports have previously suggested that CXCR4 is
over-expressed in a variety of tumors including gastric, ovarian,
pancreatic, melanoma, renal, cervical, colon, and hematological
malignancies (Manu et al., 2011, 2013; Shanmugam et al., 2011b).
However, there are no substantial studies elaborating upon the
detailed mechanism(s) of CXCR4 over-expression in tumor cells
(Kulbe et al., 2005).
Genetic mutations in von Hippel Lindau tumor suppressor
gene (Staller et al., 2003), PAX3- and PAX7-FKHR gene fusion
(Libura et al., 2002), angiogenic growth factors (Bachelder
et al., 2002; Schioppa et al., 2003), deregulated NF-κB (Zlotnik,
2006), and pro-inflammatory cytokines (Kulbe et al., 2005)
have all been implicated in CXCR4 over-expression. Recent
evidence implicates that EGFR, c-erbB2 and its encoding
gene HER2/neu, can also regulate CXCR4 expression at the
post-transcriptional level in breast cancer cells (Benovic and
Marchese, 2004; Arya et al., 2007). Moreover, studies have
implicated CXCR4 over-expression to cancer metastasis and
are an indicator of poor prognosis and overall patient survival
(Xu et al., 2015). A high level of expression of CXCR4
was significantly associated with a greater risk of bone
metastasis. Bone metastasis occurs significantly more often
in CXCR4 positive patients (13.1%) as compared to CXCR4
negative patients (2.4%; P = 0.008) (Hung et al., 2014). In
a recent article, Ashour et al. (2014, 2016) demonstrated
that TQ can also inhibit NF-κB phosphorylation and its
regulated gene products, such as interleukin-8 and chemokines,
in a dose- and time-dependent manner in hepatocellular
carcinoma cells. Therefore, CXCR4 appears to be a novel
therapeutic target for the treatment of metastatic breast
cancer. It has also been suggested that CXCR4 may be
degraded by ligand-dependent lysosomal degradation (Fernandis
et al., 2004) and by atrophin-interacting protein 4 mediated
polyubiquitination and subsequent degradation (Bhandari et al.,
2007).
CXCL12 is the only ligand for CXCR4 and acts as
autocrine/paracrine growth factor for several cancers.
Interestingly, we found that CXCL12 was able to increase
the levels of CXCR4 in TNBC cells. In a recent study, it has
been reported that the overexpression of both CXCR4 and
CXCL12 mRNA in glioblastoma cancer stem cells (GBM-
CSC) can control proliferation, invasion and angiogenesis.
CXCL12 secretion from CXCR4 expressing cells supports
the occurrence of autocrine/paracrine mechanism in GBM
CSCs, in human meningioma and pituitary adenoma cells
(Gatti et al., 2013). Furthermore, in another study by Borrello
et al. (2005), it was reported that transforming oncogene
RET/PTC1 in human papillary thyroid carcinoma can induce the
expression of CXCL12 and its receptor CXCR4, thus triggering
autocrine proliferation of thyroid carcinoma cells (Borrello et al.,
2005). Our results also demonstrate that TQ can substantially
suppress CXCR4 expression in TNBC cells and this modulation
was observed to occur at the transcriptional level and not
mediated by either ligand-dependent lysosomal or proteasomal
degradation. Because TQ was observed to modulate inhibit both
NF-κB DNA binding and reporter gene expression, we further
investigated the effects of TQ on CXCL12-induced invasion and
migration in TNBC cell lines. We found that pre-incubation
with TQ completely blocked CXCL12-induced migration and
invasive potential of TNBC cells. Furthermore, TQ failed to
abrogate inhibit invasion or migration of cells in p65 deleted
cells.
We also investigated for the first time the potential effect
of TQ on breast cancer cell bone metastasis in a breast
cancer mouse model. CXCL12 signaling via CXCR4 has an
important physiological role in hematopoietic stem cell homing
to the bone marrow (Balkwill, 2004b; Xu et al., 2015). This
signaling axis also plays a critical part in breast cancer
cell metastasis by increasing chemotaxis to regions of high
CXCL12 expression such as bone, lung, and brain (Arya
et al., 2007). Therefore, down-regulation of CXCR4 in triple
negative metastatic breast cancer cells could greatly decrease
their metastatic potential. In our study we also determined the
anti-cancer effects in a tumor-bearing chick embryo model.
The CAM assay has been used extensively as a model for
studying angiogenesis due to the accessibility and visibility of
the developing blood vessels (Siveen et al., 2014a). However,
recent studies have shown that tumor cells can grow readily on
the CAM in an immunocompromised environment (Sys et al.,
2013).
Tumor bearing chick embryos have been used to study
anti-cancer effects of drugs (Abe et al., 2011; Busch et al.,
2013). In our study, we implanted breast cancer cells onto
the CAM and evaluated the effects of TQ on tumor growth
and vascularity. We found that TQ dose-dependently inhibited
tumor growth and potently reduced the tumor vascular volume.
Furthermore, we found that intraperitoneal administration
of TQ at doses of 2 or 4 mg/kg b.w for 4 weeks could
inhibit the growth and metastasis of breast cancer tumors. TQ
significantly suppressed lung, bone, and brain metastasis, as
evidenced by a decrease in bioluminescence signals in these
organs. It is of note that patients with terminal breast cancer
exhibit severe bone destruction associated with osteolytic lesions
(Mundy, 2002). We further evaluated the inhibitory effect of
Frontiers in Pharmacology | www.frontiersin.org 12 December 2018 | Volume 9 | Article 1294
fphar-09-01294 December 1, 2018 Time: 14:6 # 13
Shanmugam et al. Thymoquinone Abrogates CXCR4/SDF1 Signaling
TQ on osteolytic bone metastasis in nude mice inoculated
with MDA-MB-231-luc+ cells into the left cardiac ventricle.
Bone metastasis was found to be significantly suppressed in
the TQ treated group, and the number of osteolytic lesions in
the mandibles, femora, and tibiae were markedly decreased, as
indicated by bioluminescence imaging. Western blot analysis
of tumors obtained from the lung and brain also showed
a decrease in the expression of CXCR4 and Ki67. In fact,
upon TQ treatment, there was a marked reduction in thinning
of bones, as evidenced by H&E staining. In addition, IHC
analysis of lung, brain, and bone tumors revealed inhibition
of CXCR4 expression. Overall, TQ was well tolerated at the
doses tested and was effective in suppressing the metastasis
of TNBC cells. In conclusion, TQ inhibited NF-κB regulated
CXCR4 expression, migration, as well as invasion of the
TNBC cells, and markedly suppressed bone metastasis by
suppressing NF-κB activation cascade. Further studies are
warranted as TQ as its clinically relevant doses are yet to be
determined.
AUTHOR CONTRIBUTIONS
GS, APK, KHBT, LL, RH, KSA, AC, TA, MS, and SA conceived
the project. GS, APK, KHBT, LL, RH, and KSA designed the
experiments. MS, AH, CW, YY, and APK carried out the
experiments and analysis the data. MS, GS, AKo, APK, KSA, and
FA wrote and corrected the paper.
FUNDING
This work was supported by NUHS basic seed grant to KHBT.
APK was supported by grants from National Medical Research
Council of Singapore, NCIS Yong Siew Yoon Research Grant
through donations from the Yong Loo Lin Trust. APK and
RH were also supported by the National Research Foundation
Singapore and the Singapore Ministry of Education under its
Research Centers of Excellence initiative to Cancer Science
Institute of Singapore, National University of Singapore.
REFERENCES
Abe, C., Uto, Y., Nakae, T., Shinmoto, Y., Sano, K., Nakata, H., et al. (2011).
Evaluation of the in vivo radiosensitizing activity of etanidazole using tumor-
bearing chick embryo. J. Radiat. Res. 52, 208–214. doi: 10.1269/jrr.10122
Abukhader, M. M. (2012). The effect of route of administration in thymoquinone
toxicity in male and female rats. Indian J. Pharm. Sci. 74, 195–200. doi: 10.4103/
0250-474X.106060
Alvarez, R. H., Valero, V., and Hortobagyi, G. N. (2010). Emerging targeted
therapies for breast cancer. J. Clin. Oncol. 28, 3366–3379. doi: 10.1200/JCO.
2009.25.4011
Arya, M., Ahmed, H., Silhi, N., Williamson, M., and Patel, H. R. (2007). Clinical
importance and therapeutic implications of the pivotal CXCL12-CXCR4
(chemokine ligand-receptor) interaction in cancer cell migration. Tumour Biol.
28, 123–131. doi: 10.1159/000102979
Ashour, A. E., Abd-Allah, A. R., Korashy, H. M., Attia, S. M., Alzahrani,
A. Z., Saquib, Q., et al. (2014). Thymoquinone suppression of the human
hepatocellular carcinoma cell growth involves inhibition of IL-8 expression,
elevated levels of TRAIL receptors, oxidative stress and apoptosis. Mol. Cell.
Biochem. 389, 85–98. doi: 10.1007/s11010-013-1930-1
Ashour, A. E., Ahmed, A. F., Kumar, A., Zoheir, K. M., Aboul-Soud, M. A., Ahmad,
S. F., et al. (2016). Thymoquinone inhibits growth of human medulloblastoma
cells by inducing oxidative stress and caspase-dependent apoptosis while
suppressing NF-kappaB signaling and IL-8 expression. Mol. Cell. Biochem. 416,
141–155. doi: 10.1007/s11010-016-2703-4
Bachelder, R. E., Wendt, M. A., and Mercurio, A. M. (2002). Vascular endothelial
growth factor promotes breast carcinoma invasion in an autocrine manner by
regulating the chemokine receptor CXCR4. Cancer Res. 15, 7203–7206.
Balkwill, F. (2004a). Cancer and the chemokine network. Nat. Rev. Cancer 4,
540–550. doi: 10.1038/nrc1388
Balkwill, F. (2004b). The significance of cancer cell expression of the chemokine
receptor CXCR4. Semin. Cancer Biol. 14, 171–179.
Benovic, J. L., and Marchese, A. (2004). A new key in breast cancer metastasis.
Cancer Cell 6, 429–430. doi: 10.1016/j.ccr.2004.10.017
Bhandari, D., Trejo, J., Benovic, J. L., and Marchese, A. (2007). Arrestin-2 interacts
with the ubiquitin-protein isopeptide ligase atrophin-interacting protein 4 and
mediates endosomal sorting of the chemokine receptor CXCR4. J. Biol. Chem.
282, 36971–36979. doi: 10.1074/jbc.M705085200
Bishayee, A., and Sethi, G. (2016). Bioactive natural products in cancer prevention
and therapy: progress and promise. Semin. Cancer Biol. 40–41, 1–3. doi: 10.
1016/j.semcancer.2016.08.006
Borrello, M. G., Alberti, L., Fischer, A., Degl’innocenti, D., Ferrario, C.,
Gariboldi, M., et al. (2005). Induction of a proinflammatory program in normal
human thyrocytes by the RET/PTC1 oncogene. Proc. Natl. Acad. Sci. U.S.A. 102,
14825–14830. doi: 10.1073/pnas.0503039102
Bray, F., Jemal, A., Grey, N., Ferlay, J., and Forman, D. (2012). Global
cancer transitions according to the human development index (2008-2030):
a population-based study. Lancet Oncol. 13, 790–801. doi: 10.1016/S1470-
2045(12)70211-5
Busch, C., Krochmann, J., and Drews, U. (2013). The chick embryo as an
experimental system for melanoma cell invasion. PLoS One 8:e53970. doi: 10.
1371/journal.pone.0053970
Chua, A. W., Hay, H. S., Rajendran, P., Shanmugam, M. K., Li, F., Bist, P.,
et al. (2010). Butein downregulates chemokine receptor CXCR4 expression and
function through suppression of NF-kappaB activation in breast and pancreatic
tumor cells. Biochem. Pharmacol. 80, 1553–1562. doi: 10.1016/j.bcp.2010.
07.045
Contag, C. H., Jenkins, D., Contag, P. R., and Negrin, R. S. (2000). Use of reporter
genes for optical measurements of neoplastic disease in vivo. Neoplasia 2, 41–52.
doi: 10.1038/sj.neo.7900079
Dai, X., Ahn, K. S., Kim, C., Siveen, K. S., Ong, T. H., Shanmugam, M. K., et al.
(2015). Ascochlorin, an isoprenoid antibiotic inhibits growth and invasion
of hepatocellular carcinoma by targeting STAT3 signaling cascade through
the induction of PIAS3. Mol. Oncol. 9, 818–833. doi: 10.1016/j.molonc.2014.
12.008
Dey, A., Wong, E., Kua, N., Teo, H. L., Tergaonkar, V., and Lane, D. (2008).
Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK
pathway and represses NF kappaB activity: implications for cancer therapy. Cell
Cycle. 7, 3759–3767. doi: 10.4161/cc.7.23.7213
El Mezayen, R., El Gazzar, M., Nicolls, M. R., Marecki, J. C., Dreskin, S. C.,
and Nomiyama, H. (2006). Effect of thymoquinone on cyclooxygenase
expression and prostaglandin production in a mouse model of allergic airway
inflammation. Immunol. Lett. 106, 72–81. doi: 10.1016/j.imlet.2006.04.012
El-Mahdy, M. A., Zhu, Q., Wang, Q. E., Wani, G., and Wani, A. A.
(2005). Thymoquinone induces apoptosis through activation of caspase-8 and
mitochondrial events in p53-null myeloblastic leukemia HL-60 cells. Int. J.
Cancer 117, 409–417. doi: 10.1002/ijc.21205
El-Mahmoudy, A., Matsuyama, H., Borgan, M. A., Shimizu, Y., El-Sayed, M. G.,
Minamoto, N., et al. (2002). Thymoquinone suppresses expression of inducible
nitric oxide synthase in rat macrophages. Int. Immunopharmacol. 2, 1603–1611.
doi: 10.1016/S1567-5769(02)00139-X
Fernandis, A. Z., Prasad, A., Band, H., Klosel, R., and Ganju, R. K. (2004).
Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast
cancer cells. Oncogene 23, 157–167. doi: 10.1038/sj.onc.1206910
Gali-Muhtasib, H., Diab-Assaf, M., Boltze, C., Al-Hmaira, J., Hartig, R.,
Roessner, A., et al. (2004). Thymoquinone extracted from black seed triggers
Frontiers in Pharmacology | www.frontiersin.org 13 December 2018 | Volume 9 | Article 1294
fphar-09-01294 December 1, 2018 Time: 14:6 # 14
Shanmugam et al. Thymoquinone Abrogates CXCR4/SDF1 Signaling
apoptotic cell death in human colorectal cancer cells via a p53-dependent
mechanism. Int. J. Oncol. 25, 857–866.
Gali-Muhtasib, H., Roessner, A., and Schneider-Stock, R. (2006). Thymoquinone:
a promising anti-cancer drug from natural sources. Int. J. Biochem. Cell Biol. 38,
1249–1253. doi: 10.1016/j.biocel.2005.10.009
Gatti, M., Pattarozzi, A., Bajetto, A., Wurth, R., Daga, A., Fiaschi, P., et al. (2013).
Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of
human glioblastoma stem-like cells affecting self-renewal activity. Toxicology
314, 209–220. doi: 10.1016/j.tox.2013.10.003
Hasanpourghadi, M., Looi, C. Y., Pandurangan, A. K., Sethi, G., Wong, W. F., and
Mustafa, M. R. (2017). Phytometabolites targeting the warburg effect in cancer
cells: a mechanistic review. Curr. Drug Targets 18, 1086–1094. doi: 10.2174/
1389450117666160401124842
Helbig, G., Christopherson, K. W., Bhat-Nakshatri, P., Kumar, S., Kishimoto, H.,
Miller, K. D., et al. (2003). NF-kappaB promotes breast cancer cell migration
and metastasis by inducing the expression of the chemokine receptor CXCR4.
J. Biol. Chem. 278, 21631–21638. doi: 10.1074/jbc.M300609200
Hung, C. S., Su, H. Y., Liang, H. H., Lai, C. W., Chang, Y. C., Ho, Y. S., et al. (2014).
High-level expression of CXCR4 in breast cancer is associated with early distant
and bone metastases. Tumour Biol. 35, 1581–1588. doi: 10.1007/s13277-013-
1218-9
Hwang, Y. S., Han, S. S., Kim, K. R., Ye-Jin, L., Sun-Kyung, L., Kwang-Kyun, P.,
et al. (2015). Validating of the pre-clinical mouse model for metastatic
breast cancer to the mandible. J. Appl. Oral. Sci. 23, 3–8. doi: 10.1590/1678-
775720140158
Jenkins, D. E., Oei, Y., Hornig, Y. S., Yu, S. F., Dusich, J., Purchio, T., et al. (2003a).
Bioluminescent imaging (BLI) to improve and refine traditional murine models
of tumor growth and metastasis. Clin. Exp. Metastasis 20, 733–744.
Jenkins, D. E., Yu, S. F., Hornig, Y. S., Purchio, T., and Contag, P. R. (2003b). In vivo
monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-
C6 cells in murine models of human prostate cancer. Clin. Exp. Metastasis 20,
745–756.
Jia, L. Y., Shanmugam, M. K., Sethi, G., and Bishayee, A. (2016). Potential role of
targeted therapies in the treatment of triple-negative breast cancer. Anticancer
Drugs 27, 147–155. doi: 10.1097/CAD.0000000000000328
Kaseb, A. O., Chinnakannu, K., Chen, D., Sivanandam, A., Tejwani, S., Menon, M.,
et al. (2007). Androgen receptor and E2F-1 targeted thymoquinone therapy for
hormone-refractory prostate cancer. Cancer Res. 67, 7782–7788. doi: 10.1158/
0008-5472.CAN-07-1483
Kato, M., Kitayama, J., Kazama, S., and Nagawa, H. (2003). Expression pattern
of CXC chemokine receptor-4 is correlated with lymph node metastasis in
human invasive ductal carcinoma. Breast Cancer Res. 5, R144–R150. doi: 10.
1186/bcr627
Keeley, E. C., Mehrad, B., and Strieter, R. M. (2010). CXC chemokines in cancer
angiogenesis and metastases. Adv. Cancer Res. 106, 91–111. doi: 10.1016/S0065-
230X(10)06003-3
Kukreja, P., Abdel-Mageed, A. B., Mondal, D., Liu, K., and Agrawal, K. C.
(2005). Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived
factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial
migration: role of MEK/ERK signaling pathway-dependent NF-kappaB
activation. Cancer Res. 65, 9891–9898. doi: 10.1158/0008-5472.CAN-05-1293
Kulbe, H., Hagemann, T., Szlosarek, P. W., Balkwill, F. R., and Wilson, J. L. (2005).
The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine
receptor expression on ovarian cancer cells. Cancer Res. 65, 10355–10362. doi:
10.1158/0008-5472.CAN-05-0957
Kumar, G., and Manjunatha, B. (2013). Metastatic tumors to the jaws and oral
cavity. J. Oral. Maxillofac Pathol. 17, 71–75. doi: 10.4103/0973-029X.110737
Lee, J. H., Kim, B., Jin, W. J., Kim, J. W., Kim, H. H., Ha, H., et al. (2014).
Trolox inhibits osteolytic bone metastasis of breast cancer through both
PGE2-dependent and independent mechanisms. Biochem. Pharmacol. 91, 51–
60. doi: 10.1016/j.bcp.2014.06.005
Li, F., Rajendran, P., and Sethi, G. (2010). Thymoquinone inhibits proliferation,
induces apoptosis and chemosensitizes human multiple myeloma cells through
suppression of signal transducer and activator of transcription 3 activation
pathway. Br. J. Pharmacol. 161, 541–554. doi: 10.1111/j.1476-5381.2010.
00874.x
Li, F., Zhang, J., Arfuso, F., Chinnathambi, A., Zayed, M. E., Alharbi, S. A., et al.
(2015). NF-kappaB in cancer therapy. Arch. Toxicol. 89, 711–731. doi: 10.1007/
s00204-015-1470-4
Libura, J., Drukala, J., Majka, M., Tomescu, O., Navenot, J. M., Kucia, M., et al.
(2002). CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and
regulates locomotion, chemotaxis, and adhesion. Blood 100, 2597–2606. doi:
10.1182/blood-2002-01-0031
Liu, L., Ahn, K. S., Shanmugam, M. K., Wang, H., Shen, H., Arfuso, F., et al. (2018).
Oleuropein induces apoptosis via abrogating NF-kappaB activation cascade in
estrogen receptor-negative breast cancer cells. J. Cell. Biochem. doi: 10.1002/jcb.
27738 [Epub ahead of print].,
Manu, K. A., Shanmugam, M. K., Ong, T. H., Subramaniam, A., Siveen,
K. S., Perumal, E., et al. (2013). Emodin suppresses migration and invasion
through the modulation of CXCR4 expression in an orthotopic model of
human hepatocellular carcinoma. PLoS One 8:e57015. doi: 10.1371/journal.
pone.0057015
Manu, K. A., Shanmugam, M. K., Rajendran, P., Li, F., Ramachandran, L., Hay,
H. S., et al. (2011). Plumbagin inhibits invasion and migration of breast and
gastric cancer cells by downregulating the expression of chemokine receptor
CXCR4. Mol. Cancer 10:107. doi: 10.1186/1476-4598-10-107
Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., et al. (2001).
Involvement of chemokine receptors in breast cancer metastasis. Nature 410,
50–56. doi: 10.1038/35065016
Mundy, G. R. (2002). Metastasis to bone: causes, consequences and therapeutic
opportunities. Nat. Rev. Cancer 2, 584–593. doi: 10.1038/nrc867
Perez, E. A., and Spano, J. P. (2012). Current and emerging targeted therapies for
metastatic breast cancer. Cancer 118, 3014–3025. doi: 10.1002/cncr.26356
Puar, Y. R., Shanmugam, M. K., Fan, L., Arfuso, F., Sethi, G., and Tergaonkar, V.
(2018). Evidence for the involvement of the master transcription factor NF-
kappaB in cancer initiation and progression. Biomedicines 27:6. doi: 10.3390/
biomedicines6030082
Rehemtulla, A., Stegman, L. D., Cardozo, S. J., Gupta, S., Hall, D. E., Contag,
C. H., et al. (2000). Rapid and quantitative assessment of cancer treatment
response using in vivo bioluminescence imaging. Neoplasia 2, 491–495. doi:
10.1038/sj.neo.7900121
Roepke, M., Diestel, A., Bajbouj, K., Walluscheck, D., Schonfeld, P., Roessner, A.,
et al. (2007). Lack of p53 augments thymoquinone-induced apoptosis and
caspase activation in human osteosarcoma cells. Cancer Biol. Ther. 6, 160–169.
doi: 10.4161/cbt.6.2.3575
Salem, M. L. (2005). Immunomodulatory and therapeutic properties of the Nigella
sativa L. seed. Int. Immunopharmacol. 5, 1749–1770. doi: 10.1016/j.intimp.
2005.06.008
Scatena, C. D., Hepner, M. A., Oei, Y. A., Dusich, J. M., Yu, S. F., Purchio, T.,
et al. (2004). Imaging of bioluminescent LNCaP-luc-M6 tumors: a new animal
model for the study of metastatic human prostate cancer. Prostate 59, 292–303.
doi: 10.1002/pros.20003
Schioppa, T., Uranchimeg, B., Saccani, A., Biswas, S. K., Doni, A., Rapisarda, A.,
et al. (2003). Regulation of the chemokine receptor CXCR4 by hypoxia. J. Exp.
Med. 198, 1391–1402. doi: 10.1084/jem.20030267
Sethi, G., Ahn, K. S., and Aggarwal, B. B. (2008a). Targeting nuclear factor-kappa
B activation pathway by thymoquinone: role in suppression of antiapoptotic
gene products and enhancement of apoptosis. Mol. Cancer Res. 6, 1059–1070.
doi: 10.1158/1541-7786.MCR-07-2088
Sethi, G., Shanmugam, M. K., Ramachandran, L., Kumar, A. P., and Tergaonkar, V.
(2012). Multifaceted link between cancer and inflammation. Biosci. Rep. 32,
1–15. doi: 10.1042/BSR20100136
Sethi, G., Sung, B., and Aggarwal, B. B. (2008b). Nuclear factor-kappaB activation:
from bench to bedside. Exp. Biol. Med. 233, 21–31.
Sethi, G., and Tergaonkar, V. (2009). Potential pharmacological control of the NF-
kappaB pathway. Trends Pharmacol. Sci. 30, 313–321. doi: 10.1016/j.tips.2009.
03.004
Shanmugam, M. K., Arfuso, F., Kumar, A. P., Wang, L., Goh, B. C., Ahn,
K. S., et al. (2018). Modulation of diverse oncogenic transcription factors
by thymoquinone, an essential oil compound isolated from the seeds of
Nigella sativa Linn. Pharmacol. Res. 129, 357–364. doi: 10.1016/j.phrs.2017.
11.023
Frontiers in Pharmacology | www.frontiersin.org 14 December 2018 | Volume 9 | Article 1294
fphar-09-01294 December 1, 2018 Time: 14:6 # 15
Shanmugam et al. Thymoquinone Abrogates CXCR4/SDF1 Signaling
Shanmugam, M. K., Kannaiyan, R., and Sethi, G. (2011a). Targeting cell signaling
and apoptotic pathways by dietary agents: role in the prevention and treatment
of cancer. Nutr. Cancer 63, 161–173. doi: 10.1080/01635581.2011.523502
Shanmugam, M. K., Manu, K. A., Ong, T. H., Ramachandran, L., Surana, R.,
Bist, P., et al. (2011b). Inhibition of CXCR4/CXCL12 signaling axis by
ursolic acid leads to suppression of metastasis in transgenic adenocarcinoma
of mouse prostate model. Int. J. Cancer 129, 1552–1563. doi: 10.1002/ijc.
26120
Shanmugam, M. K., Rajendran, P., Li, F., Nema, T., Vali, S., Abbasi, T., et al.
(2011c). Ursolic acid inhibits multiple cell survival pathways leading to
suppression of growth of prostate cancer xenograft in nude mice. J. Mol. Med.
89, 713–727. doi: 10.1007/s00109-011-0746-2
Shanmugam, M. K., Kumar, A. P., Tan, B. K. H., and Sethi, G. (2013). Role of NF-
κB in tumorigenesis. For. Immunopathol. Dis. Ther. 4, 187–203. doi: 10.1615/
ForumImmunDisTher.2013008382
Shanmugam, M. K., Lee, J. H., Chai, E. Z., Kanchi, M. M., Kar, S., Arfuso, F., et al.
(2016). Cancer prevention and therapy through the modulation of transcription
factors by bioactive natural compounds. Semin. Cancer Biol. 40-41, 35–47.
doi: 10.1016/j.semcancer.2016.03.005
Shanmugam, M. K., Nguyen, A. H., Kumar, A. P., Tan, B. K., and Sethi, G.
(2012). Targeted inhibition of tumor proliferation, survival, and metastasis by
pentacyclic triterpenoids: potential role in prevention and therapy of cancer.
Cancer Lett. 320, 158–170. doi: 10.1016/j.canlet.2012.02.037
Shanmugam, M. K., Rane, G., Kanchi, M. M., Arfuso, F., Chinnathambi, A., Zayed,
M. E., et al. (2015). The multifaceted role of curcumin in cancer prevention and
treatment. Molecules 20, 2728–2769. doi: 10.3390/molecules20022728
Shoieb, A. M., Elgayyar, M., Dudrick, P. S., Bell, J. L., and Tithof, P. K. (2003).
In vitro inhibition of growth and induction of apoptosis in cancer cell lines by
thymoquinone. Int. J. Oncol. 22, 107–113. doi: 10.3892/ijo.22.1.107
Siveen, K. S., Ahn, K. S., Ong, T. H., Shanmugam, M. K., Li, F., Yap, W. N.,
et al. (2014a). Y-tocotrienol inhibits angiogenesis-dependent growth of human
hepatocellular carcinoma through abrogation of AKT/mTOR pathway in an
orthotopic mouse model. Oncotarget 5, 1897–1911.
Siveen, K. S., Mustafa, N., Li, F., Kannaiyan, R., Ahn, K. S., Kumar, A. P.,
et al. (2014b). Thymoquinone overcomes chemoresistance and enhances the
anticancer effects of bortezomib through abrogation of NF-kappaB regulated
gene products in multiple myeloma xenograft mouse model. Oncotarget 5,
634–648.
Staller, P., Sulitkova, J., Lisztwan, J., Moch, H., Oakeley, E. J., and Krek, W. (2003).
Chemokine receptor CXCR4 downregulated by von hippel-lindau tumour
suppressor pVHL. Nature 425, 307–311. doi: 10.1038/nature01874
Sys, G. M., Lapeire, L., Stevens, N., Favoreel, H., Forsyth, R., Bracke, M., et al.
(2013). The in ovo CAM-assay as a xenograft model for sarcoma. J. Vis. Exp.
17:e50522. doi: 10.3791/50522
Tang, C. H., Sethi, G., and Kuo, P. L. (2014). Novel medicines and strategies in
cancer treatment and prevention. Biomed. Res. Int. 2014:474078. doi: 10.1155/
2014/474078
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., and Jemal, A. (2015).
Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87–108. doi: 10.3322/caac.
21262
van der Horst, G., and van der Pluijm, G. (2012). Preclinical models that illuminate
the bone metastasis cascade. Recent Results Cancer Res. 192, 1–31. doi: 10.1007/
978-3-642-21892-7_1
Wang, C., Kar, S., Lai, X., Cai, W., Arfuso, F., Sethi, G., et al. (2018). Triple
negative breast cancer in Asia: an insider’s view. Cancer Treat. Rev. 62, 29–38.
doi: 10.1016/j.ctrv.2017.10.014
Woo, C. C., Hsu, A., Kumar, A. P., Sethi, G., and Tan, K. H. (2013). Thymoquinone
inhibits tumor growth and induces apoptosis in a breast cancer xenograft mouse
model: the role of p38 MAPK and ROS. PLoS One 8:e75356. doi: 10.1371/
journal.pone.0075356
Woo, C. C., Kumar, A. P., Sethi, G., and Tan, K. H. (2012). Thymoquinone:
potential cure for inflammatory disorders and cancer. Biochem. Pharmacol. 83,
443–451. doi: 10.1016/j.bcp.2011.09.029
Woo, C. C., Loo, S. Y., Gee, V., Yap, C. W., Sethi, G., Kumar, A. P., et al.
(2011). Anticancer activity of thymoquinone in breast cancer cells: possible
involvement of PPAR-gamma pathway. Biochem. Pharmacol. 82, 464–475. doi:
10.1016/j.bcp.2011.05.030
Worthen, D. R., Ghosheh, O. A., and Crooks, P. A. (1998). The in vitro anti-tumor
activity of some crude and purified components of blackseed, Nigella sativa L.
Anticancer Res. 18, 1527–1532.
Xu, C., Zhao, H., Chen, H., and Yao, Q. (2015). CXCR4 in breast cancer: oncogenic
role and therapeutic targeting. Drug Des. Dev. Ther. 9, 4953–4964. doi: 10.2147/
DDDT.S84932
Yang, S. F., Weng, C. J., Sethi, G., and Hu, D. N. (2013). Natural bioactives and
phytochemicals serve in cancer treatment and prevention. Evid. Based Comp.
Alternat. Med. 2013:698190. doi: 10.1155/2013/698190
Yi, T., Cho, S. G., Yi, Z., Pang, X., Rodriguez, M., Wang, Y., et al.
(2008). Thymoquinone inhibits tumor angiogenesis and tumor growth
through suppressing AKT and extracellular signal-regulated kinase signaling
pathways. Mol. Cancer Ther. 7, 1789–1796. doi: 10.1158/1535-7163.MCT-
08-0124
Zhang, J., Ahn, K. S., Kim, C., Shanmugam, M. K., Siveen, K. S., Arfuso, F., et al.
(2016). Nimbolide-induced oxidative stress abrogates STAT3 signaling cascade
and inhibits tumor growth in transgenic adenocarcinoma of mouse prostate
model. Antioxid. Redox Signal. 24, 575–589. doi: 10.1089/ars.2015.6418
Zlotnik, A. (2006). Chemokines and cancer. Int. J. Cancer 119, 2026–2029. doi:
10.1002/ijc.22024
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Shanmugam, Ahn, Hsu, Woo, Yuan, Tan, Chinnathambi,
Alahmadi, Alharbi, Koh, Arfuso, Huang, Lim, Sethi and Kumar. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Pharmacology | www.frontiersin.org 15 December 2018 | Volume 9 | Article 1294
